Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6iGlen Clack,Sercan Aksoy,Meritxell Bellet- Ezquerra,Begoña Bermejo,Cagatay Arslan,Maria Castro-Henriques,Irfan Cicin,Mahmut Gumus, Carmen Hinojo-González,Nuri Karadurmus, Denisse Lee Cervantes,Rebeca Lozano Mejorada,Emmanuel de la Mora Jimenez,Fernando Moreno Antón,Sonia Pernas,Timothy Pluard, Carlos Zuloaga Fernandez del Valle,Ozan yazıcı,Stuart McIntoshCancer Research（2024）引用 0|浏览39AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
